Latest news

Debiopharm invests over 30 million on innovation when its workforce jumped 33% in Valais in one year

Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response

Debiopharm and Genome & Company Join Forces to Create New Highly Specific Therapies For Cancer Patients

Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America

Debiopharm et la HES-SO Valais-Wallis célèbrent 20 ans de partenariat public-privé en collaborant au développement d’une nouvelle technologie de marquage…

Debiopharm Group™ inaugure son site de production et son laboratoire de recherche après 18 mois de travaux, à Martigny.

Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland)

Continuity as Debiopharm Group™ management moves forward

Abionic wins the ‘Prix Debiopharm Valais pour les Sciences de la Vie’ for its innovative biomedical device for diagnostic testing